Systemic enzymes are protein-digesting enzymes, mostly proteases, taken orally on an empty stomach with the intention that they enter the bloodstream and act throughout the body rather than just in the gut. Unlike digestive enzymes, which break down food in the stomach and intestines, systemic enzymes are designed to reach circulation and influence inflammation, fibrin buildup, immune signaling, and tissue repair. The concept has deep roots in European and Japanese medicine, and a growing body of clinical research has started mapping what these enzymes actually do once they get past the digestive tract.
How Systemic Enzymes Differ from Digestive Enzymes
Every enzyme supplement you swallow faces the same hostile environment: stomach acid and the body’s own digestive proteases, which exist specifically to shred proteins into amino acids. Digestive enzyme supplements are meant for that environment. They help break down food, and their job is done in the gut. Systemic enzymes, by contrast, need to survive that environment intact so they can be absorbed through the intestinal wall and enter the bloodstream. That is why timing matters so much. Taking a systemic enzyme with a meal defeats the purpose because the enzyme gets occupied digesting food proteins instead of passing into circulation. The standard recommendation is to take them on an empty stomach, typically 30 to 60 minutes before eating or at least two hours after.
To protect the enzyme from stomach acid, many formulations use enteric coatings or microparticle delivery systems. Research on these coatings has shown they can preserve the structural integrity of proteins under simulated gastric conditions, allowing the enzymes to reach the small intestine intact where absorption can occur.1PubMed. Enzyme structure and function protection from gastrointestinal degradation using enteric coatings Without that protection, a large percentage of the active enzyme would be destroyed before it ever had a chance to work systemically.
How They Reduce Inflammation
The anti-inflammatory action of systemic enzymes is probably their most-studied benefit and the one that drives most of the clinical interest. These enzymes work through several overlapping pathways. They can scavenge reactive oxygen species, the unstable molecules that fuel oxidative stress in inflamed tissue. They can interfere with the production of pro-inflammatory signaling molecules called cytokines, degrade cytokines already circulating in the blood, and block the release of cytokines from immune cells.2PubMed Central. Enzyme-Based Anti-Inflammatory Therapeutics for Inflammatory Diseases In practical terms, the effect is a dampening of the inflammatory cascade without completely shutting down the immune response, which is an important distinction from drugs like corticosteroids that suppress immunity more broadly.
A randomized, double-blind, placebo-controlled trial in people with knee osteoarthritis offers a concrete example of what this looks like clinically. After eight weeks of treatment with an oral enzyme combination, the anti-inflammatory marker IL-10 rose by roughly 41% more than in the placebo group, a statistically significant difference. Pain scores also improved. However, other markers of systemic inflammation did not show significant between-group differences, which suggests the anti-inflammatory effect of enzyme therapy may be selective rather than sweeping.3RMD Open. Oral enzyme combination therapy reduces systemic inflammation, urinary CTXII and pain in knee osteoarthritis: a proof-of-mechanism, randomised, crossover, double-blind, placebo-controlled trial That selectivity is actually reassuring from a safety standpoint. A therapy that modulates one or two inflammatory pathways rather than flattening the entire immune response carries fewer risks of leaving you vulnerable to infection.
Breaking Down Fibrin
Fibrin is a tough, mesh-like protein your body produces to stop bleeding. It is essential for wound repair, but the body sometimes overproduces it or fails to clean it up afterward. Excess fibrin contributes to blood clots, scar tissue, and the stiffening of tissues that comes with chronic inflammation or aging. Fibrinolytic enzymes cleave fibrin, and when they fail to keep up with fibrin production, the result can be cardiovascular problems including deep vein thrombosis and stroke.4PubMed Central. Diverse origins of fibrinolytic enzymes: A comprehensive review
Several systemic enzymes target fibrin directly. Nattokinase, derived from the fermented soybean dish natto, is the most prominent. Research has documented its fibrinolytic activity along with effects on blood pressure, atherosclerosis, lipid levels, and platelet aggregation.5PubMed Central. Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases Serrapeptase also shows fibrinolytic properties alongside its anti-inflammatory and anti-edema effects.6PubMed Central. Serratiopeptidase: Insights into the therapeutic applications The fibrin-clearing action is one reason systemic enzyme therapy sometimes appeals to people dealing with conditions where excess fibrin plays a role, from post-surgical adhesions to chronic pain syndromes.
It is worth noting that the body’s own fibrinolytic system, centered on the enzyme plasmin, is the gold standard for clot breakdown. Research comparing human and porcine versions of fibrinolytic components has found substantial differences in efficiency. Porcine plasmin, for example, demonstrated a roughly three-fold to seven-fold higher catalytic rate for breaking down fibrin compared to human plasmin, depending on the fibrin source.7PubMed Central. Differences and Compatibility between Human and Porcine Fibrinolytic Components toward Plasmin Generation and Fibrin Degradation This kind of research matters because it shows the fibrinolytic system is not one-size-fits-all, and supplemental enzymes from microbial or animal sources may behave quite differently from the enzymes your body already makes.
The Major Players in Systemic Enzyme Supplements
Most systemic enzyme products contain a blend of enzymes from animal, plant, and microbial sources. Understanding the individual enzymes helps you read labels with more confidence.
Serrapeptase
Originally isolated from bacteria in the gut of silkworms, serrapeptase (also called serratiopeptidase) is a protease with documented anti-inflammatory, analgesic, anti-edema, anti-biofilm, and fibrinolytic properties.6PubMed Central. Serratiopeptidase: Insights into the therapeutic applications A clinical trial in orthopedic trauma patients found that adjunctive serrapeptase at 30 mg was associated with lower pain scores and faster resolution of all clinical signs of inflammation compared to controls, with significant differences across all measured parameters by day fifteen.8PubMed Central. Efficacy of high-dose serrapeptase (serratiopeptidase) in inflammation among orthopedic trauma patients Serrapeptase has gained popularity in Europe and Asia as a post-surgical recovery aid, though it remains less well-known in North America.
Nattokinase
Nattokinase is the standout enzyme for cardiovascular applications. Produced by the bacterium Bacillus subtilis during the fermentation of soybeans, it has been used in Japanese cuisine for centuries. Its range of documented activities extends beyond clot dissolution to include blood-pressure lowering, anti-atherosclerotic, and lipid-lowering effects.5PubMed Central. Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases People on blood-thinning medications should be cautious with nattokinase because its fibrinolytic activity could compound the anticoagulant effect, potentially raising bleeding risk.
Bromelain and Papain
Bromelain comes from pineapple stems, papain from papaya. Both are cysteine proteases with overlapping but not identical effects. In an animal model of intestinal inflammation, both enzymes reduced markers of oxidative stress and pro-inflammatory cytokines, with bromelain showing the stronger protective effect overall.9PubMed Central. Therapeutic effect of bromelain and papain on intestinal injury induced by indomethacin in male rats Cell-culture research on a bromelain-papain complex has shown decreases in expression of inflammatory genes including those coding for TNF-α, IL-6, and MMP9 across colon, breast, and skin cell lines, suggesting the combination can modulate inflammation and edema pathways in multiple tissue types.10Scientific Reports. Investigation of the effects of a Kiperin Bromelain & Papain complex in normal colon, mammary, and skin cells Bromelain is one of the most accessible systemic enzymes and appears in many multi-enzyme formulations alongside serrapeptase or nattokinase.
Swelling After Surgery
Reducing post-operative edema is one of the older and better-documented applications of systemic enzyme therapy. A randomized, double-blind, placebo-controlled trial in patients undergoing orthognathic (jaw) surgery measured facial swelling using ultrasound and found significantly less soft-tissue thickness in the enzyme group compared to placebo, especially on days five and fifteen after surgery. The researchers concluded that systemic enzyme therapy significantly decreases postoperative edema and could spare patients from long-term corticosteroid use.11PubMed. A prospective, randomized, double-blind, placebo-controlled clinical trial comparing the efficacy of systemic enzyme therapy for edema control in orthognathic surgery using ultrasound scan to measure facial swelling
A separate trial compared systemic proteolytic enzyme therapy against diclofenac, a common anti-inflammatory drug, in patients having third-molar (wisdom tooth) extractions. The enzyme group and the diclofenac group ended up statistically comparable in both swelling and pain across the observation period, with no significant difference between them.12PubMed. The effects of systemic proteolytic enzyme therapy on pain and swelling in third molar surgery equal to diclofenac therapy: a prospective randomized double blinded clinical trial That is a telling result. Being as effective as a well-established NSAID, without the gastrointestinal side effects that can come with chronic NSAID use, is a meaningful practical advantage for patients who need anti-inflammatory support but want to avoid drug-related risks.
Athletic Recovery and Muscle Soreness
Delayed-onset muscle soreness, that deep ache that sets in a day or two after intense exercise, is driven by micro-damage to muscle fibers and the inflammatory response that follows. Systemic enzyme therapy has been tested in this context with some encouraging results. A two-stage, double-blinded trial in healthy active adults measured the impact of systemic enzyme therapy after exhaustive eccentric exercise, the type that causes the most muscle damage. In the enzyme group, the drop in physical performance was smaller: about 2.8% at three hours versus 6.2% in the placebo group. Physical performance returned to baseline at 24 hours with enzymes but not until 48 hours with placebo.13PubMed Central. Effects of a systemic enzyme therapy in healthy active adults after exhaustive eccentric exercise: a randomised, two-stage, double-blinded, placebo-controlled trial
Another randomized, placebo-controlled study looking at a multi-enzyme complex for delayed-onset muscle soreness found significant improvements in pain questionnaire scores and pressure-pain thresholds in the thigh muscle. Biomarkers of muscle damage, including creatine kinase and lactate dehydrogenase, also trended downward in the enzyme group.14Journal of Nutrition Science Research. Multi-Enzyme Complex for the Management of Delayed Onset Muscle Soreness after Eccentric Exercise: A Randomized, Double Blind, Placebo Controlled Study The pattern across these trials is consistent: systemic enzymes appear to speed recovery by reducing the inflammatory component of exercise-induced muscle damage, not by preventing the damage itself. You still get sore, just less so and for a shorter period.
Biofilm Disruption
One of the more surprising applications of enzyme therapy has nothing to do with inflammation or fibrin. Bacterial biofilms, the slimy colonies that bacteria form on surfaces including medical devices and wound tissue, are notoriously difficult to treat with antibiotics alone because the protective matrix shields the bacteria inside. Enzymes, particularly proteases and glycosidases, can degrade the structural components of that matrix and expose the bacteria to antimicrobial treatment.15PubMed Central. Microbial enzymes as powerful natural anti-biofilm candidates
Research has shown that co-treatment of proteases with antibiotics can have a synergistic effect, thoroughly degrading preformed biofilms produced by a range of bacteria.16npj Biofilms and Microbiomes. Strategy to combat biofilms: a focus on biofilm dispersal enzymes In an animal model of burn-wound infection by Pseudomonas aeruginosa, combining biofilm-disrupting enzymes with the antibiotic tobramycin significantly reduced tissue damage, bacterial load, and inflammatory markers compared to tobramycin alone.17PubMed Central. Anti-Biofilm Enzymes-Assisted Antibiotic Therapy against Burn Wound Infection by Pseudomonas aeruginosa This area of enzyme research is still largely preclinical, but it points to a future where enzyme therapies could play a role in combating antibiotic-resistant infections, a major public-health problem.
Scar Tissue and Fibrosis
Fibrosis, the excessive buildup of collagen-rich scar tissue, is a common feature of chronic injury and disease in organs from the lungs to the liver. Regardless of the injury type or location, the underlying problem is the same: too much extracellular matrix and not enough breakdown of that matrix.18PubMed Central. Extracellular Targets to Reduce Excessive Scarring in Response to Tissue Injury Systemic proteolytic enzymes are hypothesized to help rebalance this equation by degrading excess fibrin and other matrix proteins, potentially slowing or reducing scar formation. The evidence here is mostly mechanistic and preclinical rather than drawn from large human trials, so it is best described as a plausible application that still needs stronger proof from clinical research.
Anecdotally, practitioners of systemic enzyme therapy have long pointed to scar tissue reduction as one of the therapy’s benefits, particularly for post-surgical adhesions and conditions like Peyronie’s disease. The theoretical basis is solid, given that fibrinolytic and proteolytic enzymes do, by definition, break down the proteins that form scar tissue. But the clinical trial data has not kept pace with the theory, and anyone considering enzyme therapy for fibrosis should keep that gap in mind.
Immune Complex Clearance
Your immune system sometimes produces antibody-antigen clusters called circulating immune complexes. In healthy people, these are cleared efficiently. In certain disease states, particularly autoimmune conditions and allergic diseases, these complexes can accumulate and trigger chronic inflammation in tissues where they deposit, including the kidneys, joints, and blood vessel walls. Systemic enzyme therapy has been investigated as a way to accelerate the breakdown of these complexes. In patients with bronchial asthma and digestive comorbidities, treatment that included systemic enzyme therapy was associated with reduced levels of circulating immune complexes, total IgE, and blood eosinophil counts.19Asthma and allergy. Enterosorption and Systemic Enzymotherapy in Treatment of Patients with Exacerbation of Bronchial Asthma and Comorbid Pathology of the Digestive Organs The idea is that proteolytic enzymes in the bloodstream physically chew up these immune complexes, reducing the inflammatory burden they create.
Do Your Own Enzyme Levels Drop with Age?
One argument frequently made in favor of systemic enzyme supplementation is that your body’s own production of proteolytic enzymes declines as you get older. There is some animal evidence for this. A study measuring proteolytic enzyme activity across different age groups of rats found that trypsin activity was highest in young animals and decreased with age.20PubMed. Proteolytic enzyme activity as a result of aging Extrapolating from rats to humans is always a leap, but the finding aligns with the broader observation that many enzymatic and metabolic processes become less efficient as we age. If your body is producing fewer of the enzymes responsible for cleaning up fibrin, modulating inflammation, and clearing immune complexes, the logic of supplementation at least makes intuitive sense, even if the human data specifically mapping age-related enzyme decline to clinical outcomes remains thin.
This is one of those areas where the supplement industry has gotten ahead of the science. The claim “your enzymes decline with age, so you need to supplement” is plausible and directionally supported, but the precise magnitude of decline, the age at which it becomes clinically meaningful, and the degree to which oral supplementation compensates for it are all questions that have not been definitively answered in human trials.
Practical Considerations and Safety
Systemic enzymes are generally well-tolerated, with gastrointestinal discomfort being the most commonly reported side effect. However, there are a few practical points worth knowing before you start taking them.
- Timing: Take them on an empty stomach. With food, they act as digestive enzymes and lose their systemic potential.
- Blood thinners: Because several systemic enzymes have fibrinolytic and antiplatelet activity, they can interact with anticoagulant medications like warfarin or direct oral anticoagulants. If you are on blood thinners, talk to your doctor before adding nattokinase or any enzyme blend.
- Surgery: For the same reason, most practitioners recommend stopping systemic enzyme supplements one to two weeks before elective surgery to reduce bleeding risk.
- Dosing: Enzyme activity is measured in units specific to each enzyme type, not simply by milligrams of powder. A product listing milligrams without activity units is not giving you enough information to judge potency.
- Enteric coating: Look for products that use enteric coating or acid-resistant delivery systems. Without stomach-acid protection, you are likely paying for enzymes that get destroyed before they reach your bloodstream.
Regulatory classification varies by country. In parts of Europe, systemic enzyme preparations are registered as medicines and prescribed by physicians. In the United States, they are sold as dietary supplements, which means they do not go through the same approval process as pharmaceutical drugs. The quality and potency of supplement products can vary significantly between manufacturers, so sourcing from reputable brands that provide third-party testing is worth the extra effort.
Where Enzymes Are Heading in Research
The biofilm work mentioned earlier represents one of the more exciting frontiers. Antibiotic resistance is a growing crisis, and enzymes that can strip away the protective shields bacteria build around themselves could become valuable tools in wound care and infection management. In burn-wound models, the combination of biofilm-disrupting enzymes with conventional antibiotics already outperforms antibiotics alone in reducing bacterial load and tissue damage.17PubMed Central. Anti-Biofilm Enzymes-Assisted Antibiotic Therapy against Burn Wound Infection by Pseudomonas aeruginosa Translating that into clinical use for chronic wounds, implant-associated infections, and hospital-acquired infections is an active area of investigation.
Formulation science is also advancing. The challenge of getting a fragile protein past the stomach and into the bloodstream in functional form is being addressed with increasingly sophisticated microparticle and nanoparticle delivery systems.1PubMed. Enzyme structure and function protection from gastrointestinal degradation using enteric coatings Better delivery means higher bioavailability, which could make lower doses more effective and reduce the number of capsules people need to take. Current protocols often call for multiple large capsules several times a day, which is a compliance barrier for many users. If delivery technology improves enough, systemic enzyme therapy could become more practical for everyday use and more appealing for clinical trials seeking to establish definitive efficacy data.